Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TRAVERE THERAPEUTICS, INC.

(TVTX)
  Report
Delayed Quote. Delayed Nasdaq - 12/01 04:00:00 pm
27.99 USD   -1.96%
11/11Travere Therapeutics to Present at Upcoming Investor Conferences
GL
11/09INSIDER SELL : Travere Therapeutics
MT
11/03INSIDER SELL : Travere Therapeutics
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/24/2021 11/26/2021 11/29/2021 11/30/2021 12/01/2021 Date
30.3(c) 29.03(c) 28.47(c) 28.55(c) 27.99(c) Last
460 737 399 329 469 784 1 238 231 666 855 Volume
+3.27% -4.19% -1.93% +0.28% -1.96% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 225 M - -
Net income 2021 -172 M - -
Net cash position 2021 299 M - -
P/E ratio 2021 -9,69x
Yield 2021 -
Sales 2022 222 M - -
Net income 2022 -187 M - -
Net cash position 2022 148 M - -
P/E ratio 2022 -9,33x
Yield 2022 -
Capitalization 1 714 M 1 714 M -
EV / Sales 2021 6,29x
EV / Sales 2022 7,04x
Nbr of Employees 262
Free-Float 95,5%
More Financials
Company
Travere Therapeutics, Inc. (Travere) is an integrated biopharmaceutical company the is focused on identifying, developing and delivering therapies to people with rare diseases. TravereÔÇÖs products include Chenodal (chenodiol tablets), holbam (cholic acid capsules) and Thiola and Thiola EC (tiopronin tablets). Chenodal, which is for the treatment of patients suffering from gallstones in whom surgery poses an... 
Sector
Biotechnology & Medical Research
Calendar
11/30 | 10:30amPresentation
More about the company
Ratings of Travere Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about TRAVERE THERAPEUTICS, INC.
11/11Travere Therapeutics to Present at Upcoming Investor Conferences
GL
11/09INSIDER SELL : Travere Therapeutics
MT
11/03INSIDER SELL : Travere Therapeutics
MT
11/02Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week..
GL
10/29Travere Therapeutics' Q3 Adjusted Loss Widens, Revenue Grows
MT
10/29Wedbush Lifts Price Target on Travere Therapeutics to $20 From $14, Maintains Neutral R..
MT
10/29Travere Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
10/29Quarterly Report (Form 10-Q)
PU
10/28Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Pr..
PU
10/28Travere Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
10/28TRAVERE : Q3 Earnings Snapshot
AQ
10/28Earnings Flash (TVTX) TRAVERE THERAPEUTICS Reports Q3 Revenue $68.2M, vs. Street Est of..
MT
10/28Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Pr..
GL
10/14TRAVERE THERAPEUTICS : to Report Third Quarter 2021 Financial Results
AQ
10/14TRAVERE THERAPEUTICS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
More news
News in other languages on TRAVERE THERAPEUTICS, INC.
10/29La perte ajustée de Travere Therapeutics au troisième trimestre se creuse, mais le chif..
10/28Earnings Flash (TVTX) TRAVERE THERAPEUTICS annonce un chiffre d'affaires de 68,2 millio..
09/16AKTIEN SCHWEIZ SCHLUSS : SMI erobert Marke von 12'000 Punkten zurück
09/16Résumé des principales informations économiques du jeudi 16 septembre
09/16Vifor acquiert des droits sur un anti-cancéreux expérimental avancé
More news
Analyst Recommendations on TRAVERE THERAPEUTICS, INC.
More recommendations
Chart TRAVERE THERAPEUTICS, INC.
Duration : Period :
Travere Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRAVERE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 27,99 $
Average target price 36,00 $
Spread / Average Target 28,6%
EPS Revisions
Managers and Directors
Eric M. Dube President, Chief Executive Officer & Director
Laura M. Clague Chief Financial Officer
Gary A. Lyons Chairman
William E. Rote Senior VP, Head-Research & Development
Noah L. Rosenberg Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
TRAVERE THERAPEUTICS, INC.2.70%1 714
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE310.30%80 784
WUXI APPTEC CO., LTD.30.33%67 780
REGENERON PHARMACEUTICALS31.76%65 932
VERTEX PHARMACEUTICALS-13.26%52 122